Lamotrigin Medochemie: Uses, Dosage & Side Effects

What Is Lamotrigin Medochemie and What Is It Used For?

Lamotrigin Medochemie is a generic formulation of lamotrigine, a medication that belongs to the phenyltriazine class of anticonvulsants. Unlike many other antiepileptic drugs, lamotrigine was specifically designed and developed as an anticonvulsant from the outset, rather than being repurposed from another therapeutic area. It was first approved for clinical use in the early 1990s and has since become one of the most widely prescribed antiepileptic drugs worldwide, with extensive clinical experience spanning more than three decades.

Lamotrigine exerts its therapeutic effects primarily through the blockade of voltage-sensitive sodium channels. When neurons become excessively active, as occurs during epileptic seizures, voltage-sensitive sodium channels open rapidly and repeatedly, allowing sodium ions to flood into nerve cells and perpetuate abnormal electrical discharges. Lamotrigine preferentially binds to these channels in their inactive (closed) state, stabilizing them and preventing the rapid repetitive firing that underlies seizure activity. This mechanism is sometimes described as use-dependent or frequency-dependent blockade, meaning that lamotrigine has a greater effect on neurons that are firing abnormally fast, while having relatively little impact on normal neuronal activity at therapeutic doses.

In addition to sodium channel blockade, lamotrigine inhibits the presynaptic release of glutamate, the principal excitatory neurotransmitter in the central nervous system. Excessive glutamate release contributes to both seizure generation and the excitotoxic neuronal damage that can accompany prolonged seizures. By reducing glutamate release, lamotrigine provides an additional layer of protection against seizure propagation. There is also evidence suggesting that lamotrigine may modulate voltage-sensitive calcium channels and the hyperpolarization-activated cation current (Ih), which could contribute to its broad spectrum of antiepileptic activity.

Lamotrigine is approved and widely used for the following clinical indications:

• Epilepsy in adults and adolescents (13 years and older): As monotherapy or adjunctive therapy for focal (partial) seizures with or without secondary generalization, and for generalized tonic-clonic seizures. Lamotrigine may also be used for seizures associated with Lennox-Gastaut syndrome.
• Epilepsy in children (2 to 12 years): As adjunctive therapy for focal seizures, generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Monotherapy of typical absence seizures may also be considered.
• Bipolar I disorder in adults (18 years and older): For the prevention of depressive episodes in patients whose condition is predominantly characterized by depressive episodes. Lamotrigine is used as maintenance therapy, not for the acute treatment of manic or depressive episodes.

The International League Against Epilepsy (ILAE) considers lamotrigine a first-line treatment option for both focal and generalized tonic-clonic seizures. A landmark comparative effectiveness trial (the SANAD study, published in The Lancet) found lamotrigine to be the most effective and best-tolerated first-line treatment for focal epilepsy when considering both seizure control and side effect profile. For generalized epilepsy, lamotrigine is among the recommended options, though valproate remains the first-line choice when not contraindicated.

In the context of bipolar disorder, lamotrigine occupies a unique therapeutic niche. While lithium and valproate are primarily effective for preventing manic episodes, lamotrigine has demonstrated superior efficacy in preventing depressive episodes, which are often the most disabling and predominant phase of bipolar I disorder. The pivotal clinical trials by Calabrese and colleagues, as well as by Bowden and colleagues, demonstrated that lamotrigine significantly delayed the time to intervention for a depressive episode compared with placebo, while also showing some benefit in delaying manic episodes. International guidelines, including those from the British Association for Psychopharmacology (BAP) and the Canadian Network for Mood and Anxiety Treatments (CANMAT), recommend lamotrigine as a first-line maintenance treatment for bipolar disorder, particularly in patients with a predominantly depressive course.

What Should You Know Before Taking Lamotrigin Medochemie?

Contraindications

The only absolute contraindication to lamotrigine is known hypersensitivity (allergy) to lamotrigine or to any of the excipients in the formulation. If you have previously experienced a serious skin reaction while taking lamotrigine, you must not restart the medication. Even if you previously tolerated a different brand or formulation of lamotrigine, you should inform your doctor about any past adverse reactions to any lamotrigine product.

It is important to note that while there are few absolute contraindications, several situations require special caution, dose modifications, or careful monitoring, as described below. Your doctor will weigh the benefits against the risks in each case and determine whether lamotrigine is appropriate for you.

Warnings and Precautions

The incidence of serious skin reactions (SJS/TEN) in clinical trials has been estimated at approximately 1 in 1,000 adults and 1 in 300 to 500 children. While any skin rash during lamotrigine treatment should be taken seriously, not all rashes indicate SJS/TEN. Benign rashes do occur and may resolve even with continued treatment. However, because it is impossible to reliably distinguish between a benign rash and the early stages of a serious skin reaction at the outset, the general recommendation is to discontinue lamotrigine at the first sign of any rash, unless the rash is clearly unrelated to the medication. After a rash develops, the decision about whether to restart lamotrigine should be made carefully by a specialist.

Additional precautions and situations requiring medical discussion include:

• Hemophagocytic lymphohistiocytosis (HLH): Rare cases of HLH, a potentially life-threatening immune activation syndrome, have been reported with lamotrigine. Symptoms include unexplained high fever, fatigue, swollen lymph nodes, liver enlargement, and abnormal blood test results. If HLH is suspected, treatment should be discontinued and appropriate medical care initiated.
• Suicidal ideation and behavior: As with all antiepileptic drugs, there is a small but statistically significant increased risk of suicidal thoughts and behavior. A meta-analysis by the FDA found that patients taking antiepileptic drugs had approximately twice the risk of suicidal ideation compared with placebo. Patients, families, and caregivers should be alert to changes in mood, behavior, or the emergence of suicidal thoughts, particularly during the initial months of treatment or after dose changes.
• Renal impairment: Lamotrigine metabolites are eliminated by the kidneys. In patients with significant renal impairment, metabolite accumulation may occur, and dose adjustments may be necessary based on clinical response and tolerability.
• Hepatic impairment: Lamotrigine is metabolized in the liver. Patients with moderate to severe hepatic impairment require reduced doses (typically 50% reduction for moderate and 75% for severe impairment).
• Brugada syndrome: Lamotrigine may unmask Brugada syndrome, a rare inherited cardiac condition that can cause dangerous arrhythmias. If you have a personal or family history of Brugada syndrome or unexplained sudden cardiac death, inform your doctor before starting lamotrigine.
• Treatment withdrawal: Abrupt discontinuation of lamotrigine in patients with epilepsy can precipitate rebound seizures, including status epilepticus. If lamotrigine needs to be discontinued, the dose should be reduced gradually over a period of at least 2 weeks, unless safety concerns require a more rapid withdrawal (such as in the case of a serious skin reaction).

Pregnancy and Breastfeeding

Lamotrigine is one of the most extensively studied antiepileptic drugs in pregnancy, with data from multiple pregnancy registries involving tens of thousands of exposures. The available evidence indicates that lamotrigine monotherapy is associated with a relatively low rate of major congenital malformations, generally in the range of 2-3%, which is comparable to the background rate in the general population. Data from the North American Antiepileptic Drug Pregnancy Registry, the UK Epilepsy and Pregnancy Register, and the EURAP registry have consistently supported this finding.

However, important pharmacokinetic changes occur during pregnancy that significantly affect lamotrigine levels. Due to increased glucuronidation (the primary metabolic pathway for lamotrigine) driven by rising estrogen levels during pregnancy, lamotrigine blood levels can decrease by as much as 50-65% during the second and third trimesters. This decline can lead to breakthrough seizures, which pose serious risks to both the mother and the developing fetus, including physical injury from falls, fetal hypoxia, and in extreme cases, maternal and fetal death. For this reason, regular monitoring of lamotrigine blood levels during pregnancy is essential, and dose increases are often required. After delivery, lamotrigine levels can rise rapidly as estrogen levels fall, necessitating prompt dose reduction to avoid toxicity.

Women with epilepsy who are pregnant or planning to become pregnant should never stop lamotrigine abruptly without medical supervision. The risks of uncontrolled seizures to both mother and baby generally outweigh the risks of continued medication. All women of childbearing potential taking lamotrigine should discuss family planning with their neurologist or epilepsy specialist.

Lamotrigine is excreted into breast milk at significant concentrations, reaching approximately 40-60% of maternal serum levels in some studies. While the clinical significance of this exposure to the nursing infant is not fully established, most expert guidelines consider breastfeeding to be acceptable during lamotrigine treatment, provided the infant is monitored for potential adverse effects such as excessive sedation, poor feeding, or skin rashes. The benefits of breastfeeding generally outweigh the potential risks of lamotrigine exposure through breast milk.

Driving and Operating Machinery

Lamotrigine can cause dizziness, drowsiness, blurred or double vision, and impaired coordination, particularly during the initial treatment period and during dose escalation. These effects may impair your ability to drive safely or operate machinery. You should not drive or perform tasks requiring alertness until you know how lamotrigine affects you. Additionally, patients with epilepsy must comply with local driving regulations regarding seizure-free intervals, which vary by jurisdiction.

How Does Lamotrigin Medochemie Interact with Other Drugs?

Drug interactions with lamotrigine are among the most clinically important of any antiepileptic drug, and understanding them is essential for safe prescribing. Lamotrigine is primarily metabolized by glucuronidation in the liver, catalyzed by UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A4 and UGT2B7. Any medication that inhibits or induces these enzymes can significantly alter lamotrigine blood levels, necessitating dose adjustments. Unlike many other drugs, lamotrigine is not significantly metabolized by the cytochrome P450 (CYP) enzyme system.

Major Interactions

The following interactions are of major clinical significance and require dose modifications:

Minor and Other Interactions

The following interactions are of lesser clinical significance but should still be considered:

A particularly important clinical scenario involves the interaction between lamotrigine and combined oral contraceptives. During the active pill weeks (when ethinylestradiol is being taken), lamotrigine levels are reduced by approximately 50%, which can lead to breakthrough seizures in women with epilepsy or recurrence of depressive symptoms in women with bipolar disorder. During the pill-free week, the removal of the enzyme-inducing effect of ethinylestradiol causes lamotrigine levels to rise rapidly, potentially leading to dose-related side effects such as dizziness, diplopia, or headache. This cyclical fluctuation in lamotrigine levels can be managed by using continuous oral contraception (without a pill-free week), choosing progestogen-only contraception, using non-hormonal contraception, or adjusting lamotrigine doses accordingly. Detailed planning with both a neurologist or psychiatrist and a gynecologist is recommended.

What Is the Correct Dosage of Lamotrigin Medochemie?

The dosing of lamotrigine is more complex than many other medications because the appropriate dose and escalation schedule depend on which other medications the patient is taking. There are essentially three dosing pathways based on concomitant therapy, and using the wrong pathway can result in either inadequate drug levels or a significantly increased risk of serious skin reactions. Your doctor will determine the correct schedule for your specific situation.

Adults – Epilepsy

Adults – Bipolar Disorder

The dosing schedule for bipolar disorder follows the same titration principles as for epilepsy, with the same three pathways depending on concomitant medications. The target maintenance dose for bipolar disorder is typically:

• Monotherapy or with non-interacting drugs: 200 mg/day (range 100–400 mg/day)
• With valproate: 100 mg/day (range 100–200 mg/day)
• With enzyme-inducing drugs (without valproate): 400 mg/day (range 300–400 mg/day)

It is important to note that lamotrigine is used for the prevention (maintenance treatment) of depressive episodes in bipolar disorder, not for the acute treatment of either depression or mania. The gradual titration over several weeks means that lamotrigine is not suitable when rapid therapeutic effect is needed.

Children (2–12 years)

Dosing in children aged 2 to 12 years is calculated based on body weight and follows the same three-pathway system. Children generally require higher doses per kilogram of body weight than adults to achieve equivalent blood levels. The starting dose ranges from 0.15 mg/kg/day (with valproate) to 0.6 mg/kg/day (with enzyme-inducing drugs). Doses should be rounded down to the nearest whole tablet, and the maximum first dose should not exceed the adult starting dose. Detailed pediatric dosing should always be determined by a specialist.

Elderly Patients

No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients are more likely to have reduced renal function, hepatic impairment, or to be taking multiple medications, all of which may necessitate more cautious dosing and slower titration. The general principle of starting at the lowest recommended dose and titrating slowly applies particularly strongly in this population.

Missed Dose

If you miss a dose, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for a missed one. If you have missed doses for several consecutive days or longer, do not restart at your current dose without consulting your doctor, as this may increase the risk of skin reactions. Re-titration (starting from a low dose and gradually increasing) may be necessary after a treatment interruption, depending on how long the medication was stopped.

Overdose

Symptoms of lamotrigine overdose may include nystagmus (involuntary eye movements), ataxia (uncoordinated movement), impaired consciousness, coma, widening of the QRS complex on ECG, and seizures. There is no specific antidote for lamotrigine overdose. Treatment is supportive and symptomatic. If overdose is suspected, seek immediate medical attention or contact a poison control center. Gastric decontamination may be considered if the overdose occurred recently. Due to lamotrigine's significant protein binding and large volume of distribution, hemodialysis is not expected to be effective in removing the drug.

What Are the Side Effects of Lamotrigin Medochemie?

Like all medicines, lamotrigine can cause side effects, although not everybody experiences them. Many side effects are dose-related, meaning they are more likely to occur at higher doses and often improve with dose reduction. Side effects also tend to be more common during the initial dose titration phase and may diminish as the body adjusts to the medication. Understanding the frequency and nature of potential side effects helps patients and caregivers know what to expect and when to seek medical attention.

The side effects are classified below according to their frequency, based on data from clinical trials and post-marketing surveillance:

It is worth noting that lamotrigine is generally well tolerated compared with many other antiepileptic drugs. It is typically weight-neutral (neither causing weight gain nor weight loss), has a relatively low impact on cognitive function, and does not cause the sedation commonly associated with drugs such as valproate, carbamazepine, or barbiturates. These characteristics make it a preferred option for many patients, particularly those concerned about the cognitive, metabolic, or sedating side effects of other antiepileptic medications.

The interaction between lamotrigine and carbamazepine deserves special mention in the context of side effects. When lamotrigine is added to carbamazepine therapy, it can increase levels of carbamazepine-10,11-epoxide (the active metabolite of carbamazepine), which can cause or worsen symptoms such as dizziness, double vision, nausea, ataxia, and headache. These symptoms may be mistakenly attributed to lamotrigine itself when they are actually caused by elevated carbamazepine-epoxide levels. Reducing the carbamazepine dose typically resolves these symptoms.

How Should You Store Lamotrigin Medochemie?

Proper storage of medications is essential to ensure their safety, efficacy, and quality throughout the shelf life. Lamotrigin Medochemie tablets should be stored at controlled room temperature, not exceeding 25°C (77°F). Brief excursions to temperatures up to 30°C (86°F) are generally acceptable for short periods during transport, but prolonged exposure to elevated temperatures should be avoided as it may degrade the active ingredient.

The tablets should be protected from light and moisture. Keep them in the original blister packaging or container until the time of use, as this provides the best protection against environmental factors that could affect the medication's stability. Do not transfer tablets to a different container unless specifically designed for pharmaceutical storage. Avoid storing the medication in the bathroom, near the kitchen sink, or in any area subject to high humidity or temperature fluctuations.

Keep this medicine out of the sight and reach of children. Consider using a lockable medicine cabinet if there are young children in the household. Do not use Lamotrigin Medochemie after the expiry date stated on the blister pack and outer carton. The expiry date refers to the last day of that month. Do not dispose of medications via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer need, as proper disposal helps protect the environment.

What Does Lamotrigin Medochemie Contain?

The active ingredient in Lamotrigin Medochemie is lamotrigine. Each tablet contains 25 mg of lamotrigine. Lamotrigine is a phenyltriazine compound (chemical name: 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine) that was specifically developed as an anticonvulsant. It is a white to pale cream-colored powder that is practically insoluble in water.

In addition to the active ingredient, each tablet contains excipients (inactive ingredients) that serve various pharmaceutical purposes. These typically include:

• Lactose monohydrate: A filler/diluent that provides bulk to the tablet. Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine without first discussing with their doctor.
• Microcrystalline cellulose: A filler and binder that helps maintain tablet integrity.
• Povidone: A binding agent that holds the tablet components together.
• Sodium starch glycolate: A disintegrant that helps the tablet break apart in the gastrointestinal tract for proper absorption.
• Magnesium stearate: A lubricant used during the manufacturing process to prevent the tablet from sticking to equipment.

Lamotrigin Medochemie tablets are available in the 25 mg strength. For patients requiring higher doses, multiple tablets may need to be taken, or your doctor may prescribe a higher-strength lamotrigine product from the same or a different manufacturer. The tablets are designed for oral administration and should be swallowed whole with water. They may be chewed, dispersed in a small volume of water, or swallowed whole, depending on the specific tablet formulation and patient preference.

As a generic medication, Lamotrigin Medochemie has demonstrated bioequivalence to the reference (innovator) product through regulatory studies, meaning that it delivers the same amount of active substance to the bloodstream at the same rate as the original branded product. This ensures equivalent therapeutic effect when used at the same dose.